
Supplementary Table 1. Meta-Regression Results for TB Screening Uptake


, h				6 - b
Predictor	Coefficient	Std. Error	p-value	95% CI
Year of publication	0.0083	0.0475	0.861	[-0.084, 0.101]
Number eligible for TB screening	0.0003	0.0006	0.657	[-0.001, 0.001]
Site type (multi-site vs. single-site)	0.2614	0.2001	0.191	[-0.130, 0.654]
Study design (cohort vs. cross-sectional)	-0.102	0.0541	0.06	[-0.208, 0.004]
AHD definition (CD4/WHO group)	0.0182	0.1278	0.874	[-0.233, 0.269]

Supplementary Table 2. Trim-and-Fill Sensitivity Analysis

Analysis	Effect Size	95% Confidence Interval	Imputed Studies
Observed	0.647	0.515-0.778	0




Supplementary Figure 1: Prevalence of TB testing uptake among patients with advanced HIV disease in Africa. Comparison between children versus adults.




Supplementary Figure 2: Prevalence of TB testing uptake among patients with advanced HIV disease in Africa. Comparison between single versus multi-site studies.

				Effect size	
Omitted study				with 95% CI	p-value
Benzekri et al, (2019)	_		•	0.7 [0.5, 0.8]	0.000
Hassan et al, (2022)			-	0.7 [0.6, 0.8]	0.000
Heller et al, (2022)		•		0.6 [0.5, 0.8]	0.000
Mbewe et al, (2022)				0.6 [0.5, 0.8]	0.000
Kanyama et al, (2022)		•		0.6 [0.5, 0.8]	0.000
Deus Lukoye, (2020)			•	0.7 [0.5, 0.8]	0.000
Marthabire, (2019)		•		0.6 [0.5, 0.8]	0.000
Wake, (2022)		•		0.6 [0.5, 0.8]	0.000
Kalyango, Najibu, (2022)		•		0.6 [0.5, 0.8]	0.000
Ahsberg et al, (2022)	_		•	0.7 [0.5, 0.8]	0.000
Nyukuri et al, (2024)			•	0.7 [0.5, 0.8]	0.000
Braide et al, (2023)	-	•		0.6 [0.5, 0.8]	0.000
Nakamwangi, (2022)		-	-	0.7 [0.6, 0.8]	0.000
Onwa et al, (2024)	_		•	0.7 [0.5, 0.8]	0.000
Kingbo, (2024)	_		•	0.7 [0.5, 0.8]	0.000
Matoga et al, (2021)				0.6 [0.5, 0.8]	0.000
Izco et al, (2021)	-	•		0.6 [0.5, 0.8]	0.000
Åhsberg et al, (2023)		•		0.6 [0.5, 0.8]	0.000
Eigege et al, (2024)				0.6 [0.5, 0.8]	0.000
	.5	.6	.7	.8	


Supplementary Figure 3: Influential analysis on the overall prevalence of TB testing uptake among patients with advanced HIV disease in Africa.



Supplementary Figure 4: Prevalence of TB testing among patients with advanced HIV disease in Africa. Comparison between children versus adults.



Supplementary Figure 5: Prevalence of TB among patients with advanced HIV disease in Africa. Comparison between single versus multi-site studies.



Supplementary Figure 6: Influential analysis on the overall prevalence of TB among patients with advanced HIV disease in Africa.

Omitted study	Effect s with 95%	
Hassan et al, (2022)	0.2 [0.1,	0.4] 0.007
Mbewe et al, (2022)	0.2 [0.0,	0.3] 0.010
Wake, (2022)	0.2 [0.0,	0.4] 0.018
Ahsberg et al, (2022)	0.2 [0.0,	0.4] 0.014
Nyukuri et al, (2024)	0.2 [0.1,	0.4] 0.009
Matoga et al, (2021)	0.2 [0.1,	0.4] 0.009
Åhsberg et al, (2023)	0.2 [0.0,	0.3] 0.023
	0 .1 .2 .3 .4	

Supplementary Figure 7